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ABSTRACT 
 
 
Introduction: Monocarboxylate transporter 4 (MCT4) is the main exporter of lactate 
out of cells. It is also a critical component in the glycolytic metabolism of cancer 
cells. In this study, stromal MCT4 in oral SCC was correlated with risk of recurrence  
(ROR), extent of primary tumor (pT) and nodal metastasis (pN), perineural invasion 
(PNI), lymphovascular invasion (LVI), HPV status, extracapsular extension (ECE) 
and positive margin.  
Methods: Clinical data were collected for 86 consecutive patients with oral HNSCC. 
Tissue microarrays (TMA) were constructed from paraffin blocks of resection 
specimens and stained for MCT4. Immunohistochemistry (IHC) staining was 
assessed and quantified by digital image analysis with Aperio software. Using a co-
localization algorithm we assessed the intensity of staining and the percentage of 
positive cells in the tumoral stromal cells. Correlations of MCT4 expression with 
clinicopathological features and survival were studied. Results: Increased IHC 
staining for MCT4 was strongly associated with an increased risk of recurrence, OR 
1.96 (95%CI: 1.17-3.40), presence of PNI, OR 2.25 (95%CI: 1.33-3.95), higher pT, 
OR 1.68 (95%CI: 0.99-2.89), higher pN, OR 2.07 (95%CI: 1.25-3.57) and presence 
of LVI, OR 2.21 (95%CI: 1.11-4.67).  We didn’t find any significant association 
between stromal MCT4 expression and HPV status, presence of ECE or positive 
margin. Conclusions: This study demonstrates that MCT4, a marker of glycolysis in 
cancer-associated stroma, is highly expressed in oral SCC. The IHC staining pattern 
of stromal MCT4 suggests that high MCT4 expression appears to be a useful 
marker for tumor progression and prognosis. We propose MCT4 serves as a new 
prognostic factor in oral SCC and can act as a potential therapeutic target marker 
considering pharmacological development of MCT4 inhibitors. 
 
INTRODUCTION  
Metabolic dysregulation is a critical process that leads to 
tumorigenesis and altering the tumor microenvironment in many 
cancers.  
Recent studies suggest that distinct metabolic compartments exist 
in HNSCC and other cancers. That metabolic coupling between 
compartments promotes tumorigenesis. 
Normal cells rely on mitochondrial oxidative phosphorylation to 
generate the energy needed for cellular processes where tumor 
cells are highly glycolytic despite the presence of oxygen. This 
phenomenon is called “the Warburg effect”.  
A Reverse Warburg Effect has been recently showed that tumor 
cells take advantage of the adjacent non-cancerous stromal cells to 
become glycolytic and the metabolic products such as lactate and 
pyruvate are then shuttled by monocarboxylate transporters (MCT1 
and MCT4) to provide fuel for tumor growth and aggressive 
behavior.  
Peritumoral staining of MCT4, as a functional biomarker, has been 
associated with poor outcomes in HNSCC. The full significance of 
metabolic coupling has not yet been cleared for oral cavity 
squamous cell carcinoma. 
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METHODS 
 
After IRB approval, records of 86 consecutive patients treated 
surgically for oral cavity squamous cell carcinoma were reviewed. 
Clinical data were collected for each patient, and each primary 
tumor sample was processed onto a tissue microarray (TMA) for 
immunohistochemistry (IHC) staining. IHC staining was performed 
for MCT4 antibody (Santa Cruz Biotechnology) . Intensity of IHC 
staining for each sample was acquired using digital pathology 
interpretation by Aperio. Intensity scores were compared against 
clinical data to identify potential biomarker for favorable or 
unfavorable tumor behavior. 
  
RESULTS   
Patient demographics and characteristics are shown in Table 1. An 
example of typical IHC staining for MCT4 and annotated region by 
Aperio is shown in Figure1. MCT 4 staining Immunohistochemistry 
(top), Note that the stroma adjacent to the tumor has stained 
strongly positive for MCT4. Annotated region by Aperio (bottom)  
 
 
 
 
 
IHC staining showed that the adjacent noncancerous cells stained 
strongly for MCT4. Higher intensity MCT4 in peri-tumoral stroma 
was significantly associated with recurrence, higher nodal stage, 
lymphovascular invasion and perineural invasion (p<0.05), (Table 
2, Figure 2). 
 
 
 
 
 
 
 
 
                                                  Figure 2. OR plots  
 
 
CONCLUSION 
Oral cavity squamous cell carcinoma showed strong MCT4 staining 
pattern that suggests metabolic compartmentalization in 
peritumoral stroma, which is associated with disease recurrence 
and other poor prognostic indicators; thus they may serve as a 
functional biomarkers for more aggressive oral cavity cancers. 
Furthermore, therapies to target metabolic coupling may be 
beneficial in patients with oral cavity cancer. 
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Table 1. Patient demographics  
Table 2. Statistical analysis  
OR 
95% CI of 
OR 
P-value 
Recurrence 1.96 1.17-3.40 0.013 
PNI 2.25 1.33-3.95 0.003 
Margins 0.77 0.31, 2.01 0.584 
LVI 2.21 1.11-4.67 0.029 
T1 vs.T3-T4 1.68 0.99-2.89 0.057 
N0 vs. N1-3 2.07 1.25-3.57 0.006 
HPV 1.10 0.50- 2.47 0.811 
ECS 0.79 0.35- 1.72 0.549 
